News
Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.
Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...
Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.
An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...
A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.
Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...
A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.
The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.
Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.
A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.
Results from the ESSENCE Phase III clinical trial published in the New England Journal of Medicine show treating patients with semaglutide can halt and even reverse liver disease. The placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results